Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
TEL AVIV, Israel, Feb. 08, 2017 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat CNS and cognitive disorders, today announced that it will report its financial results for the year ended December 31, 2016 on Wednesday, February 15, at 8:30 am Eastern Time. The company also announced a corporate presentation at the BIO CEO & Investor Conference, being held on February 13-14, 2017 at the Waldorf Astoria in New York City.
| FY2016 Financial Results Conference Call & Webcast | |
| Wednesday, February 15th @ 8:30am Eastern Time | |
| Domestic: | 855-469-0611 |
| International: | 484-756-4341 |
| Conference ID: | 63950344 |
| Webcast: | http://edge.media-server.com/m/p/662vg37q |
| Replays available through March 2, 2017 | |
| Domestic: | 855-859-2056 |
| International: | 404-537-3406 |
| Passcode: | 63950344 |
| BIO CEO & Investor Conference | |
| Tuesday, February 14th at 8:30am Eastern Time | |
| Location: | Waldorf Astoria, New York |
| Webcast: | http://www.veracast.com/webcasts/bio/ceoinvestor2017/54203411117.cfm |
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of medications to treat CNS and cognitive disorders. For more information, please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
Investor Contacts Alcobra Investor Relations Debbie Kaye US: 212-390-8964, Intl: +972-3-7299871 [email protected]
